Sign Up to like & get
recommendations!
1
Published in 2017 at "Annals of the Rheumatic Diseases"
DOI: 10.1136/annrheumdis-2017-eular.1081
Abstract: Background Denosumab is a fully human monoclonal antibody (IgG2 subclass) that inhibits bone resorption by inhibiting RANKL, a key mediator of osteoclast formation, function, and survival. Objectives To evaluate the effect of denosumab 60 mg…
read more here.
Keywords:
mitsubishi tanabe;
takeda;
denosumab;
daiichi sankyo ... See more keywords
Sign Up to like & get
recommendations!
1
Published in 2018 at "Blood"
DOI: 10.1182/blood-2018-99-110438
Abstract: The presence of MRD in patients with acute myeloid leukemia (AML) who are in morphologic remission has been shown to be a powerful predictor of eventual relapse. FMS-like tyrosine kinase 3 internal tandem duplications (FLT3-ITD)…
read more here.
Keywords:
mrd;
flt3;
daiichi sankyo;
flt3 itd ... See more keywords
Sign Up to like & get
recommendations!
1
Published in 2018 at "Blood"
DOI: 10.1182/blood-2018-99-113379
Abstract: Enhancer of zests homologous (EZH)1 and its close homolog EZH2 are component of polycomb repressive complex (PRC) 2 protein complex, and play redundant and crucial role for the maintenance of transcriptional repression by tri-methylating histone…
read more here.
Keywords:
daiichi sankyo;
honoraria research;
research;
research funding ... See more keywords
Sign Up to like & get
recommendations!
1
Published in 2019 at "Diabetes"
DOI: 10.2337/db19-2161-p
Abstract: Uncoupling protein 2 (UCP2), a mitochondrial protein, is known to be upregulated in pancreatic islets of patients with type 2 diabetes (T2DM); however, the pathological significance of the increase in UCP2 expression remained unclear. In…
read more here.
Keywords:
expression;
daiichi sankyo;
ltd;
insulin ... See more keywords